Therefore, further research into the relationship between insulin, leptin, and NAFLD stages is crucial for improving diagnostic and predictive approaches and ultimately alleviating the healthcare burden associated with advanced liver disease. This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.